Case Studies in Fungal Infections and Antifungal Therapy Wayne L. - - PowerPoint PPT Presentation

▶
case studies in fungal infections and antifungal therapy
SMART_READER_LITE
LIVE PREVIEW

Case Studies in Fungal Infections and Antifungal Therapy Wayne L. - - PowerPoint PPT Presentation

Oct 01, 2022 170 likes •971 views

Case Studies in Fungal Infections and Antifungal Therapy Wayne L. Gold MD, FRCPC Annual Meeting of the Canadian Society of Internal Medicine November 4, 2017 Disclosures No financial disclosures or industry relations. Objectives 1. Review

slide-1
SLIDE 1

Case Studies in Fungal Infections and Antifungal Therapy

Wayne L. Gold MD, FRCPC Annual Meeting of the Canadian Society of Internal Medicine November 4, 2017

slide-2
SLIDE 2

Disclosures

  • No financial disclosures or industry relations.
slide-3
SLIDE 3

Objectives

  • 1. Review infections caused by two medically important classes
  • f fungi that may be seen by specialists in Internal Medicine
  • 2. Recognize risk factors for these infections
  • 3. Understand diagnostic approaches to patients with these

infections

slide-4
SLIDE 4

Objectives

4. Review available antifungal therapies

  • Classes of antifungal agents
  • Polyenes - Amphotericin B
  • Triazoles
  • Echinocandins
  • Spectrums of activity
  • Appropriate selection by clinical syndrome
slide-5
SLIDE 5
slide-6
SLIDE 6
slide-7
SLIDE 7
slide-8
SLIDE 8
slide-9
SLIDE 9
slide-10
SLIDE 10
slide-11
SLIDE 11
slide-12
SLIDE 12

Case 1

slide-13
SLIDE 13

History

57-year-old woman

  • PMH
  • Type 2 diabetes mellitus
  • Dyslipidemia
  • Hypertension
  • Alcohol use disorder
slide-14
SLIDE 14

History of Present Illness

  • Three-day history
  • Nausea, vomiting
  • Epigastric abdominal pain
  • Recent alcohol binge
  • Dx: acute pancreatitis (imaging, biochemistry)
slide-15
SLIDE 15

History of Present Illness

  • Course complicated by ARDS and sepsis
  • infected pancreatic necrosis requiring percutaneous

drainage

  • ICU admission
  • Intubation, ventilation
  • Pressor support
  • IV piperacillin/tazobactam
  • Total parenteral nutrition - central venous catheter
slide-16
SLIDE 16

History of Present Illness

  • Defervescence followed by recurrence of fever
  • Cultures:
  • Blood
  • Endotracheal secretions
  • Drainage fluid
slide-17
SLIDE 17

Blood culture …

slide-18
SLIDE 18
slide-19
SLIDE 19

Candida species

slide-20
SLIDE 20

Candida species

  • Normal human commensal organisms
  • Skin
  • Gastrointestinal tract (mouth to anus)
  • Female genital tract
  • Expectorated sputum (oropharynx)
  • Most common species:
  • C. albicans, C. glabrata C. parapsilosis, C. tropicalis, C. krusei
slide-21
SLIDE 21

Mucocutaneous Candidiasis

  • Oropharyngeal
  • Esophageal
  • AIDS
  • Malignancies and their treatments
  • Proton pump inhibitor therapy
  • Vaginal
slide-22
SLIDE 22

Invasive Candidiasis

  • Normally non-pathogenic
  • Invasive candidiasis is the price paid for advances in

modern medical therapies

  • Primarily a nosocomial infection or associated with

ambulatory “medicalized” patients

slide-23
SLIDE 23

Host Defenses Against Invasive Candidiasis

  • Intact skin
  • Intact mucous membranes
  • Normal sphincter function
  • Normal neutrophil number and function
slide-24
SLIDE 24

Risk Factors for Invasive Candidiasis

  • Exposure to broad-spectrum antimicrobial therapy
  • Indwelling venous devices
  • Total parenteral nutrition (CVC, alimentation solution)
  • Gastrointestinal surgery
  • Neutropenia

Cytotoxic chemotherapy

  • Intestinal mucositis
  • Solid organ transplantation
  • Intravenous drug use
  • Low-birth-weight

. Adapted from Edwards JE Jr. Candida Species In Principles and Practice of Infectious Diseases 8th Edition

slide-25
SLIDE 25

Risk Factors for Invasive Candidiasis

  • Exposure to broad-spectrum antimicrobial therapy
  • Indwelling venous devices
  • Total parenteral nutrition (CVC, alimentation solution)
  • Gastrointestinal surgery
  • Neutropenia

Cytotoxic chemotherapy

  • Intestinal mucositis
  • Solid organ transplantation
  • Intravenous drug use
  • Low-birth-weight

. Adapted from Edwards JE Jr. Candida Species In Principles and Practice of Infectious Diseases 8th Edition

slide-26
SLIDE 26

Invasive / Disseminated Candidiasis

  • Bloodstream
  • Dissemination to:
  • Eyes (2-20%)
  • Bones/joints
  • Skin
  • Liver / spleen (immunocompromised hosts)
  • Heart
slide-27
SLIDE 27

Invasive Candidiasis - Diagnosis

  • Culture-based techniques
  • Blood, tissue, fluids
  • Diagnostic imaging
slide-28
SLIDE 28

What antifungal agent would you select from empiric treatment of this patient with candidemia?

slide-29
SLIDE 29

How would you treat this patient?

  • A. An echinocandin
  • Caspofungin, micafungin, anadulafungin
  • B. Fluconazole
  • C. Voriconazole
  • D. Lipid-formulation amphotericin B
slide-30
SLIDE 30

How would you treat this patient?

  • A. An echinocandin
  • Caspofungin, micafungin, anadulafungin
  • B. Fluconazole
  • C. Voriconazole
  • D. Lipid-formulation amphotericin B
slide-31
SLIDE 31
slide-32
SLIDE 32
slide-33
SLIDE 33

Empiric Treatment of Candidemia – Non-Neutropenic Patients

  • Fluconazole 800 mg iv/po in patients who are not critically

ill and without prior azole exposure

  • An echinocandin is recommended as empiric therapy when

fluconazole is patients not meeting these criteria

  • Voriconazole offers little advantage over fluconazole for

most Candida species (enhanced mould activity)

  • Amphotericin B has a greater potential for toxicity than
  • ther classes
slide-34
SLIDE 34

Treatment of Candidemia – Non-Neutropenic Patients

  • Antifungal susceptibility testing is recommended for all

bloodstream isolates

  • Candida glabrata is less susceptible to azole therapy
  • Candida krusei is intrinsically resistant to fluconazole
  • Candida parapsilosis is less susceptible to echinocandins
  • Transition from an echinocandin (if used as initial therapy) to

fluconazole is recommended once patient has stabilized and if isolate is susceptible

slide-35
SLIDE 35

What other processes of care are indicated for this patient?

slide-36
SLIDE 36

Which of the following statements is false in patients with candidemia?

  • A. A dilated ophthalmologic examination is indicated for all patients

B. Follow-up blood cultures should be performed daily until candidemia is cleared

  • C. An echocardiogram is indicated for all patients
  • D. All venous catheters should be removed / changed

E. Recommended duration of therapy is 2 weeks after documented clearance of candidemia in patients without metastatic complications

slide-37
SLIDE 37

Which of the following statements is false?

  • A. A dilated ophthalmologic examination is indicated for all patients

B. Follow-up blood cultures should be performed daily until candidemia is cleared

  • C. An echocardiogram is indicated for all patients
  • D. All venous catheters should be removed

E. Recommended duration of therapy is 2 weeks after documented clearance in patients without metastatic complications

slide-38
SLIDE 38

Treatment of Candidemia – Neutropenic Patients

  • An echinocandin or lipid formulation of amphotericin B

is recommended as initial therapy

  • During persistent neutropenia, transition to fluconazole

can be done once patient has stabilized and if isolate is susceptible

slide-39
SLIDE 39

Blood culture …

Candida albicans

slide-40
SLIDE 40

Management and Outcome

  • Treatment initiated with caspofungin
  • Hemodynamically unstable
  • Lines changed
  • Dilated ophthalmologic examination - normal
  • Day 2 – afebrile
  • Day 3 – blood culture negative
slide-41
SLIDE 41
slide-42
SLIDE 42

Case 2

slide-43
SLIDE 43

History

65-year-old man

  • PMH
  • Colorectal cancer - 2004
  • Resection, adjuvant chemotherapy
  • Metastatic progression (lung, pelvis) - 2006
  • Combination chemotherapy
  • capecitabine, irinotecan, bevacizumab
  • Treatment complicated by pulmonary embolism
slide-44
SLIDE 44

History of Present Illness

  • Four weeks prior to presentation
  • Fever, dry cough treated with course of po antibiotics
  • Two-week history of purulent sputum, night

sweats

  • Prescribed moxifloxacin
slide-45
SLIDE 45

Chest Radiograph

slide-46
SLIDE 46

History of Present Illness

  • Fever resolved
  • Increasing dyspnea, streaky hemoptysis, anorexia,

fatigue, night sweats

  • No cigarette smoking, IVDU
  • No recent travel
  • No history of TB exposure
slide-47
SLIDE 47

CT Thorax – Cavitary Lung Disease

slide-48
SLIDE 48

How would you investigate this patient?

slide-49
SLIDE 49

In consideration of a diagnosis of aspergillosis, which test is not recommended for diagnosis in this patient?

  • A. Expectorated sputum for microbiologic and

cytologic examination

  • B. Fine needle aspiration of lesion with specimens sent

for microbiologic and cytologic investigations

  • C. Bronchoscopy with specimens sent for microbiologic

and cytologic investigations

  • D. Serum galactomannan
slide-50
SLIDE 50

In consideration of a diagnosis of aspergillosis, which test is not recommended for diagnosis in this patient?

  • A. Expectorated sputum for microbiologic and

cytologic examination

  • B. Fine needle aspiration of lesion with specimens sent

for microbiologic and cytologic investigations

  • C. Bronchoscopy with specimens sent for microbiologic

and cytologic investigations

  • D. Serum galactomannan
slide-51
SLIDE 51

Invasive Aspergillosis - Diagnosis

  • Diagnostic imaging
  • Culture-based techniques
  • Tissue, fluids
slide-52
SLIDE 52

Galactomannan in the Diagnosis of Aspergillosis

  • A cell wall constituent that is released extracellularly
  • Recommended as a test for the diagnosis of invasive

aspergillosis in high-risk populations

  • Hematologic malignancy, HSCT
  • Lacks sensitivity and specificity in other populations
  • Can be applied to bronchoscopy specimens
  • May be used for screening in high-risk populations – serial

measurements

slide-53
SLIDE 53

Case – Sputum Examination

  • Sputum culture
  • Negative for bacteria and fungi
  • AFB smear –negative
slide-54
SLIDE 54

Case – Fine Needle Aspiration

  • Microbiology
  • Gram-stain - negative
  • No fungal elements seen
  • No bacterial or fungal pathogens isolated
slide-55
SLIDE 55

Cytology - Fine Needle Aspiration

slide-56
SLIDE 56

Cytology - Fine Needle Aspiration

  • Fungal elements seen – septate hyphae, 45o angles
  • Foreign material seen
  • Morphology compatible with Aspergillus species
slide-57
SLIDE 57

Aspergillus species

  • Filamentous moulds
  • Environmental organisms – ubiquitous in soil, water
slide-58
SLIDE 58

Risk Factors for Invasive Aspergillosis

  • Prolonged, profound neutropenia (>3 weeks)
  • Most common in hematological malignancies, HSCT
  • Solid organ transplantation
  • AIDS
  • Systemic corticosteroids
  • Primary immunodeficiency states (CGD)
  • Chronic lung disease
  • Anti TNFα agents
  • Marijuana use
slide-59
SLIDE 59
slide-60
SLIDE 60

Risk Factors for Invasive Aspergillosis

  • Prolonged, profound neutropenia (>3 weeks)
  • Most common in hematological malignancies, HSCT
  • Solid organ transplantation
  • AIDS
  • Systemic corticosteroids
  • Primary immunodeficiency states (CGD)
  • Chronic lung disease
  • Anti TNFα agents
  • Marijuana use
slide-61
SLIDE 61

Aspergillosis – Clinical Syndromes

  • Colonization
  • Pulmonary syndromes
  • Other organ disease
slide-62
SLIDE 62

Pulmonary Aspergillosis

  • Mycetoma – “fungus ball”
  • Angioinvasive pulmonary aspergillosis
  • Chronic necrotizing pulmonary aspergillosis
  • Obstructing bronchial aspergillosis
  • HIV/AIDS
  • Bronchial aspergillosis – lung transplantation
  • Anastamotic dehiscence
  • Allergic bronchopulmonary aspergillosis
slide-63
SLIDE 63
slide-64
SLIDE 64
slide-65
SLIDE 65
slide-66
SLIDE 66

How would you treat this patient?

slide-67
SLIDE 67

Which agent is not indicated in the treatment of aspergillosis?

  • A. Posacazole
  • B. Caspofungin
  • C. Amphtotericin B
  • D. Fluconazole
  • E. Voriconazole
slide-68
SLIDE 68

Which agent is not active against Aspergillus species?

  • A. Posacazole
  • B. Caspofungin
  • C. Amphtotericin B
  • D. Fluconazole
  • E. Voriconazole
slide-69
SLIDE 69
slide-70
SLIDE 70

Treatment of Aspergillosis

  • Voriconazole is recommended as first-line therapy for

invasive aspergillosis

  • Early therapy is recommended in patients highly suspected

for this condition while awaiting diagnostic testing results

  • Liposomal amphotercin B is recommended as alternative

therapy

  • Posaconazole and isavuconazole may be used
  • Echinocandins are second-line therapie
slide-71
SLIDE 71

Management

  • Voriconazole initiated
  • Clinical and radiographic improvement observed
slide-72
SLIDE 72
slide-73
SLIDE 73

Antifungal Therapy

slide-74
SLIDE 74
slide-75
SLIDE 75

Antifungal Therapy

  • Amphotericin B
  • Broad purpose for yeasts and moulds
  • Nephrotoxicity
  • Electrolyte disturbance (K, Mg, Ca)
  • Infusion-related side effects (“shake and bake”)
  • Less adverse reactions with lipid formulations
slide-76
SLIDE 76

Antifungal Therapy

  • Triazoles
  • Yeast; Moulds with late generation agents (VOR, POS, ISUV)
  • Enhanced mould activity with posaconazole, isavuconazole
  • Inhibitors and substrates for CYP enzymes
  • drug-drug interactions
  • May prolong QTc (isavuconazole may shorten QTc)
  • May cause hepatotoxicity
  • Voriconazole – photopsia
  • Therapeutic drug monitoring may be clinically helpful
slide-77
SLIDE 77

Antifungal Therapy

  • EchinoCANDINS -
  • CANDida; second-line agent for Apergillus species
  • Generally well tolerated
  • Few drug interactions
slide-78
SLIDE 78

Conclusions

  • Invasive fungal infections are the “collateral damage” of

advances in medical therapy

  • Candida species and Aspergillus species are clinically

important human pathogens – opportunistic pathogens

  • Increasing choices for antifungal therapy but …
  • Increasingly resistant fungi are being recognized as

human pathogens

slide-79
SLIDE 79